No News. No Press Releases. No SEC Filings. Regardless of that, shares in the penny stock of Integrated Biopharma Inc. (OTC: INBP.OB) are absolutley on fire. INBP has traded nearly 5 million shares thus far and had gained an incredible 1,220% at the HOD of 0.33. Shares in the manufacturer, distributor, marketer and seller of vitamins, nutritional supplements and herbal products, are currently trading at 0.179, up 0.154, 616%.
Integrated Biopharma’s customers are located in the U. S. INBP continues to do business as Chem International, Inc. with some of its customers and certain vendors. INBP‘s nutraceutical business includes Manhattan Drug which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers.
Looking for Cheap Stocks? Subscribe and get our next penny stock picks FREE.
INBP Stock Chart / Analysis:
Market Cap (intraday): 3.78M
Enterprise Value
(May 2, 2012): 13.27M
Price/Sales (ttm): 0.02
Revenue Per Share (ttm): 1.35
52-Week High
(5/31/2011): 0.2000
52-Week Low
(1/31/2012) 0.0193
Avg Vol (3 month): 4,129
Avg Vol (10 day): 957
5 Day History:
Percent Change 0.00%
Moving Average 0.0303
Average Volume 1,340
Shares Outstanding: 20.98M
Float: 7.93M
% Held by Insiders: 60.60%
INBP Financial Highlights
For the three months ended December 31, 2011:
Integrated Biopharma reported net sales from continuing operations had increased by $1.6 million, 28%, to $7.2 million from $5.7 million for the three months ended December 31, 2010. For the six months ended December 31, 2011, Integrated Biopharma reported net sales from continuing operations increased by $3.2 million, 26.4%, to $15.3 million from $12.1 million for the six months ended December 31, 2010.
Integrated Biopharma operating income increased from a loss of $0.1 million and $0.07 million for the three and six months ended December 31, 2010, respectively, to operating income of $0.5 million and $1.2 million for the three and six months ended December 31, 2011, respectively.
For the three and six months ended December 31, 2011, Integrated Biopharma reported that gross profit increased by approximately $0.4 million and $0.9 million from the three and six months ended December 31, 2010 and Integrated Biopharma cut selling and administrative expenses by approximately $0.2 million and $0.4 million, respectively.
Integrated Biopharma continues to focus on their core businesses and on maintaining their cost structure in line with their sales. Amazingly, Integrated Biopharma has over 120 employees.
Note: Integrated Biopharma is in default with respect to its $7.8 million outstanding principal amount of Notes Payable and its $4.5 million outstanding principal amount of Convertible Note Payable, as a result of Integrated Biopharma failing to repay the Notes Payable and Convertible Note Payable on their scheduled maturity dates.
To view the SEC filings for INBP, click here. To view their website, click here.
Bottom Line: Thus far, there have been 828 Trades on INBP with an average trade size of 6,029. Lot’s of day trading going on with this penny stock. Perhaps all the mometum has shifted from the SEFE and SNPK dumps to INBP. INBP will be an interesting one of the penny stocks to watch tomorrow.
Click To Follow Us: 
ShareMAY
